SBIR Phase I: Identifying Toxicity Pathways

Metagenx, Okemos MI

Investigators

Abstract

This Small Business Innovative Research (SBIR) Phase I project aims to develop a technology to improve the understanding of how drugs alter cellular processes. With advance in HTP technology, profiles of gene expressions, proteins and metabolites can be acquired to help elucidate the network of pathways involved in producing a specific phenotype. The project will develop a methodology that reveals the pathways that are altered and will facilitated the selection of drug candidates with the highest efficacy and minimal toxicity. Developing new drugs has become increasingly expensive, challenging and costly, not only in term of financial resources but also in toxicity. By identifying early in the drug discovery process, candidate compound with the highest probabilities of becoming successful therapies will reduce the cost of development; with the concomitant reductions in public health care costs.